Shares of biotechnology company Aptevo Therapeutics (NASDAQ:APVO) are skyrocketing today after the company announced promising data for its product candidate APVO436 for the treatment of Acute Myeloid Leukemia (AML).
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The combination of APVO436 with venetoclax and azacitidine demonstrated a 100% clinical benefit rate (CBR). Further, the combination regimen was observed as generally safe and well tolerated.
Based on this outcome, the company now plans a Phase 2 trial initiation in H2 2023. Aptevo shares have now put on nearly 75% gains over the past month.
Read full Disclosure
